Clearmind Medicine Inc.
CMND · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $2 | $3 | $1 |
| G&A Expenses | $3 | $7 | $5 | $3 |
| SG&A Expenses | $4 | $7 | $5 | $3 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $0 | $0 | $0 |
| Operating Expenses | $8 | $9 | $9 | $4 |
| Operating Income | -$8 | -$9 | -$9 | -$4 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | -$3 | -$1 | -$0 |
| Pre-Tax Income | -$5 | -$12 | -$9 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$12 | -$9 | -$4 |
| % Margin | – | – | – | – |
| EPS | -67.6 | -1,703.2 | -6,744.4 | -4,812 |
| % Growth | 96% | 74.7% | -40.2% | – |
| EPS Diluted | -67.6 | -1,703.2 | -8,688 | -4,812 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$9 | -$8 | -$4 |
| % Margin | – | – | – | – |